Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 9032 results

  1. Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. ProKnow cloud-based system for radiotherapy data storage, communication and management

    Awaiting development Reference number: GID-HTG10178 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Rezafungin for preventing invasive fungal infections after an allogeneic blood and marrow transplant [TSID12165]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Syne Covid for predicting COVID-19 outcomes MT655

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. Respirasense

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Diverticular disease

    Awaiting development Reference number: GID-QS10086 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]

    Awaiting development Reference number: GID-TA11773 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  10. Zuranolone for treating postnatal depression [ID6431]

    In development Reference number: GID-TA11356 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]

    In development Reference number: GID-TA11768 Expected publication date:  28 October 2026

    Technology appraisal guidance
    In development

  13. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Electrocautery cutting balloon treatment for pelviureteric junction obstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development